Small Bowel Cancer
14
4
6
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
7.1%
1 terminated out of 14 trials
80.0%
-6.5% vs benchmark
0%
0 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (14)
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
RCT of Mobile Apps & FitBit v. Usual Care
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy
Individualized Dose Escalation of 5-FU for Gastrointestinal Cancer
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer
Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
The Registry of Oncology Outcomes Associated with Testing and Treatment
Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
Surgery With Extended (D3) Mesenterectomy for Small Bowel Tumors
A Novel Patient Engagement Platform Among Patients With Gastrointestinal Malignancies
Prospective Analysis of Hypersensitivity Reactions to Oxaliplatin
Effects of S-1 and Capecitabine on Coronary Artery Blood Flow